Search Results for:

BREAKING NEWS: PTAB Denies IPR Institution on AbbVie’s Humira

The PTAB denied institution on two of Amgen’s IPR petitions (IPR2015-01517, IPR2015-01514) against AbbVie’s Humira.  The patents, 8,916,157 and 8,916,158, are directed to formulations of Humira, that Amgen argued were obvious because they combined adalimumab, a known antibody, with known excipients for antibody formulations.  Based on the PTAB’s claim construction…

Read More

Deal Watch: Mylan & Momenta Collaborate on 6 Biosimilar Medications

On January 8, 2016, Mylan N.V. and Momenta Pharmaceuticals, Inc. entered into an exclusive global collaboration agreement to jointly develop, manufacture, and commercialize six of Momenta’s current biosimilar medications.  According to public information about the agreement, while each company will equally share costs and profits with respect to the products,…

Read More

IPR Tracker: IPR2016-00408 and IPR2016-00409 (Boehringer Ingelheim) (U.S. Patent No. 8,889,135)

IPR2016-00408 (Boehringer Ingelheim) (U.S. Patent No. 8,889,135) Petitioner: Boehringer Ingelheim Corp., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim USA Corp. Patent: U.S. Patent No. 8,889,135 Patent Title: Methods of Administering Anti-TNFα Antibodies Patent Owner: AbbVie Biotechnology Ltd. IPR2016-00409 (Boehringer Ingelheim) (U.S. Patent No. 8,889,135) Petitioner:…

Read More